{"id":26121,"date":"2026-03-17T10:38:39","date_gmt":"2026-03-17T14:38:39","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=26121"},"modified":"2026-03-17T10:38:39","modified_gmt":"2026-03-17T14:38:39","slug":"emilys-entourage-appoints-david-a-waltz-md-as-first-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/fr\/emilys-entourage-appoints-david-a-waltz-md-as-first-chief-medical-officer\/","title":{"rendered":"Emily\u2019s Entourage Appoints David A. Waltz, MD, as First Chief Medical Officer"},"content":{"rendered":"<p style=\"text-align: center;\"><i><span style=\"font-weight: 400;\">Veteran cystic fibrosis physician-scientist and former Vertex Pharmaceuticals senior leader to help accelerate therapies for the final 10% of people with cystic fibrosis<\/span><\/i><\/p>\n<p><b><img fetchpriority=\"high\" decoding=\"async\" class=\"alignright wp-image-26123\" src=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/EE-CMO-Alert-Social-Graphic.png\" alt=\"\" width=\"440\" height=\"550\" srcset=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/EE-CMO-Alert-Social-Graphic.png 1080w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/EE-CMO-Alert-Social-Graphic-240x300.png 240w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/EE-CMO-Alert-Social-Graphic-819x1024.png 819w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/EE-CMO-Alert-Social-Graphic-768x960.png 768w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/EE-CMO-Alert-Social-Graphic-10x12.png 10w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/EE-CMO-Alert-Social-Graphic-440x550.png 440w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/EE-CMO-Alert-Social-Graphic-600x750.png 600w\" sizes=\"(max-width: 440px) 100vw, 440px\" \/>Philadelphia, PA\u2014March 17, 2026<\/b><span style=\"font-weight: 400;\">-<\/span><span style=\"font-weight: 400;\">Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating new treatments and a cure for the final 10% of people with cystic fibrosis (CF) that do not benefit from existing CFTR modulator therapies<\/span><span style=\"font-weight: 400;\">, today announced the appointment of David A. Waltz, MD, as the organization\u2019s first Chief Medical Officer (CMO).<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In this inaugural role\u2014an important milestone reflecting EE\u2019s growth and deepening investment in CF therapeutic development\u2014Dr. Waltz will work closely with Chief Scientific Officer, Chandra Ghose, PhD, to bolster EE\u2019s research and therapeutic development strategy and help propel promising discoveries funded by the organization from early scientific insight toward clinical development, positioning EE for the next era of breakthrough treatments.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">An industry leader whose career spans academic medicine, translational science, and clinical research in the biotech and pharmaceutical industries, Dr. Waltz most recently served as Vice President and Head of Cystic Fibrosis Clinical Development at Vertex Pharmaceuticals Inc., where he led the advancement of transformative CFTR modulators, including combination therapies that have reshaped the treatment landscape for roughly 90% of people with CF.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cAs Emily\u2019s Entourage continues to expand our research portfolio and push toward the next generation of treatments, bringing on our first Chief Medical Officer marks a monumental step forward for our mission,\u201d said Emily Kramer-Golinkoff, MBE, Co-Founder of EE.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cFor the final 10% of the CF community that do not benefit from existing CFTR modulator therapies, time matters. Dr. Waltz brings extraordinary experience turning scientific discoveries into lifesaving medicines. His leadership will help advance promising therapies into the clinical space quickly.\u201d\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Waltz began his career as a pediatric pulmonologist and physician-scientist at Boston Children\u2019s Hospital and Harvard Medical School, where he treated people with CF and led clinical research initiatives. He later transitioned to industry leadership roles at Novartis Institutes for BioMedical Research and Vertex Pharmaceuticals, where he played a central role in advancing multiple CF therapies through clinical development and regulatory approval.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">At EE, he will help guide the organization\u2019s growing research investments with a particular focus on translational medicine\u2014ensuring that promising discoveries move efficiently from the laboratory toward clinical trials and ultimately to people with CF in the final 10%.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cEmily\u2019s Entourage has created an extraordinary engine for innovative CF research with a relentless focus on delivering meaningful progress for the members of the community who have long been left behind,\u201d said Dr. Waltz. \u201cI\u2019m honored to join this mission and help accelerate the translation of groundbreaking science into therapies with the power to transform lives for the individuals and families still waiting.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In addition to advising on research and clinical development strategy, Dr. Waltz will serve as a key outward-facing scientific leader for EE, strengthening collaborations across academia, industry, and the broader CF community. He will represent EE at scientific forums and apply his clinical and regulatory expertise to help identify and advance new therapeutic opportunities emerging from EE\u2019s research portfolio.<\/span><\/p>\n<p><b>\u00c0 propos de l'entourage d'Emily<\/b><\/p>\n<p><span style=\"font-weight: 400;\">L'Entourage d'Emily est une organisation innovante (501(c)3) qui acc\u00e9l\u00e8re la recherche de nouveaux traitements et d'un rem\u00e8de pour les personnes appartenant au dernier 10% de la population atteinte de fibrose kystique (FK) qui ne b\u00e9n\u00e9ficient pas des th\u00e9rapies cibl\u00e9es sur les mutations actuellement disponibles. Depuis 2011, Emily's Entourage a octroy\u00e9 des millions de dollars en subventions de recherche, lanc\u00e9 une soci\u00e9t\u00e9 de th\u00e9rapie g\u00e9nique de la FK en phase clinique, d\u00e9velopp\u00e9 une base de donn\u00e9es mondiale de patients et un programme de jumelage d'essais cliniques pour acc\u00e9l\u00e9rer le recrutement d'essais cliniques, et men\u00e9 des efforts \u00e0 l'\u00e9chelle mondiale pour stimuler la recherche \u00e0 fort impact et le d\u00e9veloppement de m\u00e9dicaments. L'organisation a fait l'objet d'articles dans les m\u00e9dias nationaux, notamment dans le New York Times, STAT, CNN et People. Pour en savoir plus <\/span><a href=\"https:\/\/www.emilysentourage.org\/fr\/\"><span style=\"font-weight: 400;\">emilysentourage.org<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><b>Contact presse<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Hannah Kleckner<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Directeur du marketing et de la communication<\/span><\/p>\n<p><span style=\"font-weight: 400;\">hannah@emilysentourage.org<\/span><\/p>\n<p><span style=\"font-weight: 400;\">###<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Veteran cystic fibrosis physician-scientist and former Vertex Pharmaceuticals senior leader to help accelerate therapies for the final 10% of people with cystic fibrosis Philadelphia, PA\u2014March 17, 2026\u2014Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating new treatments and a cure for the final 10% of people with cystic fibrosis (CF) that do not benefit from existing&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/www.emilysentourage.org\/fr\/emilys-entourage-appoints-david-a-waltz-md-as-first-chief-medical-officer\/\" class=\"excerpt-read-more\">Lire la suite<\/a><\/p>","protected":false},"author":1719,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[178],"tags":[197,217,265,7,267,266],"class_list":["post-26121","post","type-post","status-publish","format-standard","hentry","category-press-releases","tag-cf-research","tag-cf-science","tag-chief-medical-officer","tag-cystic-fibrosis","tag-ee-cmo","tag-ee-staff"],"acf":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/posts\/26121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/users\/1719"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/comments?post=26121"}],"version-history":[{"count":2,"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/posts\/26121\/revisions"}],"predecessor-version":[{"id":26125,"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/posts\/26121\/revisions\/26125"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/media?parent=26121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/categories?post=26121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/fr\/wp-json\/wp\/v2\/tags?post=26121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}